ABL2 (Tyrosine-protein kinase ABL2) variants and mutations
ABL2 (also known as Tyrosine-protein kinase ABL2) is a human protein-coding gene encoding a tyrosine-protein kinase protein. Its annotated function is non-receptor tyrosine-protein kinase that plays an ABL1-overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion and receptor…. It is annotated at the cytoplasm, cytoskeleton. This analysis covers 2,040 ABL2 variants and mutations. Of these, 67% have computational variant effect predictions. Disease context includes neurodegenerative disease, lung carcinoma, and pancreatic ductal adenocarcinoma. Example ABL2 variants include G2E, G2W, and Q3E.
Variant analysis overview
- Gene: ABL2
- Protein: Tyrosine-protein kinase ABL2
- UniProt accession: P42684
- Organism: Homo sapiens
- Variants analyzed: 2040
- Variant scope: all variants
- Completed: 2026-08-28
Variant and mutation evidence
- Variant composition: 1,575 unspecified-consequence records; 1 natural variant; 204 synonymous variants; 201 missense variants; 11 in-frame deletions; 5 stop-gained variants; 35 frameshift variants; 7 in-frame insertions; 1 splice-region variants; 1 substitution
- Prediction scores: 1,376 variants have prediction scores (67% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: neurodegenerative disease, lung carcinoma, pancreatic ductal adenocarcinoma, bile duct carcinoma, esophageal adenocarcinoma, hemangioblastoma, kidney neoplasm, skin basal cell carcinoma, ovarian endometrioid adenocarcinoma with squamous differentiation, HER2 positive breast carcinoma, endometrial endometrioid adenocarcinoma, carcinoma of liver and intrahepatic biliary tract.
Protein structure and variant hotspots
- Protein features: 3 domains; 3 binding sites; 35 post-translational modification sites.
- Structural context: 402 variants have structural context.
- PTM context: 54 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable ABL2 variants
Examples include G2E, G2W, Q3E, Q3S, Q4*, Q4E, Q4R, V5E. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- G2E (p.Gly2Glu), ExAC rs771357822, gnomAD rs771357822, REVEL 0.56, CADD 23.50
- G2W (p.Gly2Trp), Ensembl rs2124889386, REVEL 0.63, CADD 28.80
- Q3E (p.Gln3Glu), Ensembl rs2124889366, REVEL 0.27, CADD 23.20
- Q3S (p.Gln3Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- Q4* (p.Gln4Ter), gnomAD rs1186686900, CADD 36.00
- Q4E (p.Gln4Glu), gnomAD rs1186686900
- Q4R (p.Gln4Arg), Ensembl rs2124889342
- V5E (p.Val5Glu), Ensembl rs2124889324, REVEL 0.41, CADD 23.20
- V5G (p.Val5Gly), Ensembl rs2124889324
- G6A (p.Gly6Ala), ExAC rs747485312, TOPMed rs747485312, gnomAD rs747485312, REVEL 0.51, CADD 25.50
- G6D (p.Gly6Asp), ExAC rs747485312, TOPMed rs747485312, gnomAD rs747485312, REVEL 0.63, CADD 26.10
- R7L (p.Arg7Leu), Ensembl rs2124889300, REVEL 0.44, CADD 24.30
- R7S (p.Arg7Ser), Ensembl rs1663422494, REVEL 0.39, CADD 24.20
- V8I (p.Val8Ile), Ensembl rs2124889284, REVEL 0.23, CADD 23.10
- G9E (p.Gly9Glu), gnomAD rs1239814206, REVEL 0.23, CADD 23.20
- G9V (p.Gly9Val), gnomAD rs1239814206, REVEL 0.42, CADD 23.40
- E10K (p.Glu10Lys), NCI-TCGA Cosmic COSV6266, REVEL 0.36, CADD 23.90, Variant assessed as somatic; high impact.
- A11G (p.Ala11Gly), gnomAD rs1214994734, REVEL 0.15, CADD 22.60
- A11V (p.Ala11Val), gnomAD rs1214994734, REVEL 0.25, CADD 23.00
- P12L (p.Pro12Leu), cosmic curated COSV62663, Ensembl rs867643650, REVEL 0.28, CADD 24.80
- P12S (p.Pro12Ser), rs866229451, ClinGen CA33898919, ClinVar RCV004154725, TOPMed rs866229451, REVEL 0.27, CADD 22.90, Uncertain significance, not specified
- P12T (p.Pro12Thr), TOPMed rs866229451, REVEL 0.28, CADD 22.80, Uncertain significance
- G13R (p.Gly13Arg), ExAC rs758479290, TOPMed rs758479290, gnomAD rs758479290, REVEL 0.30, CADD 23.20, Uncertain significance
- G13W (p.Gly13Trp), rs758479290, ClinGen CA33898907, ClinVar RCV004330766, ExAC rs758479290, REVEL 0.45, CADD 26.80, Uncertain significance, not specified
- L14F (p.Leu14Phe), ExAC rs752952462, TOPMed rs752952462, gnomAD rs752952462, REVEL 0.25, CADD 22.70
- L14H (p.Leu14His), TOPMed rs1663420846, gnomAD rs1663420846
- L14I (p.Leu14Ile), ExAC rs752952462, TOPMed rs752952462, gnomAD rs752952462, REVEL 0.15, CADD 21.50
- L14P (p.Leu14Pro), TOPMed rs1663420846, gnomAD rs1663420846, REVEL 0.42, CADD 23.00
- Q15* (p.Gln15Ter), rs1553236156, ClinGen CA343842778, ClinVar RCV000623707, Ensembl rs1553236156, CADD 36.00, Uncertain significance
- Q15H (p.Gln15His), Ensembl rs2124889178, REVEL 0.23, CADD 23.30, Uncertain significance, not specified
- Q15L (p.Gln15Leu), ExAC rs779137464, gnomAD rs779137464, REVEL 0.18, CADD 23.30
- Q16* (p.Gln16Ter), TOPMed rs1428804229, gnomAD rs1428804229, CADD 36.00
- Q16E (p.Gln16Glu), TOPMed rs1428804229, gnomAD rs1428804229, REVEL 0.21, CADD 22.30
- Q16H (p.Gln16His), NCI-TCGA Cosmic COSV1008, cosmic curated COSV10085, REVEL 0.16, CADD 23.50, Variant assessed as somatic; moderate impact.
- Q16P (p.Gln16Pro), TOPMed rs1663420207
- Q16R (p.Gln16Arg), TOPMed rs1663420207, REVEL 0.12, CADD 21.50
- P17L (p.Pro17Leu), gnomAD rs1296028787, REVEL 0.20, CADD 24.10
- P17S (p.Pro17Ser), gnomAD rs1663420071, REVEL 0.11, CADD 22.20
- P19L (p.Pro19Leu), ExAC rs753642345, gnomAD rs753642345, REVEL 0.12, CADD 22.90
- P19S (p.Pro19Ser), ExAC rs755143940, gnomAD rs755143940, REVEL 0.09, CADD 22.40
- P19T (p.Pro19Thr), cosmic curated COSV10442, ExAC rs755143940, gnomAD rs755143940, REVEL 0.09, CADD 22.00
- R20G (p.Arg20Gly), Ensembl rs1663419318, REVEL 0.44, CADD 24.90
- G21E (p.Gly21Glu), ExAC rs766129565, gnomAD rs766129565, REVEL 0.33, CADD 24.00
- G21R (p.Gly21Arg), Ensembl rs2124889082, REVEL 0.29, CADD 24.00
- G21W (p.Gly21Trp), NCI-TCGA TCGA novel, REVEL 0.39, CADD 25.10, Variant assessed as somatic; moderate impact.
- I22L (p.Ile22Leu), Ensembl rs2124889050
- I22M (p.Ile22Met), 1000Genomes rs578157802, ExAC rs578157802, gnomAD rs578157802, REVEL 0.15, CADD 22.30
- I22S (p.Ile22Ser), Ensembl rs2124889038
- I22T (p.Ile22Thr), Ensembl rs2124889038
- R23G (p.Arg23Gly), ExAC rs750363086, gnomAD rs750363086
- R23P (p.Arg23Pro), cosmic curated COSV62665, Ensembl rs2124889006, REVEL 0.38, CADD 25.30
- R23W (p.Arg23Trp), ExAC rs750363086, gnomAD rs750363086, REVEL 0.47, CADD 32.00
- G24A (p.Gly24Ala), Ensembl rs2124888987
- G24C (p.Gly24Cys), ExAC rs766986832, gnomAD rs766986832, REVEL 0.59, CADD 27.40
- G24D (p.Gly24Asp), NCI-TCGA Cosmic COSV6266, cosmic curated COSV62666, REVEL 0.47, CADD 25.60, Variant assessed as somatic; moderate impact.
- S25N (p.Ser25Asn), gnomAD rs1408623221, REVEL 0.25, CADD 22.90
- S25T (p.Ser25Thr), rs1318056, CADD 0.69
- S26G (p.Ser26Gly), TOPMed rs1663417819, REVEL 0.14, CADD 18.10
- S26N (p.Ser26Asn), TOPMed rs1195188145, gnomAD rs1195188145, REVEL 0.20, CADD 16.50
- S26R (p.Ser26Arg), ExAC rs768448217, gnomAD rs768448217, REVEL 0.21, CADD 16.70
- S26F (p.Ser26Phe), rs991511761, []
- A27V (p.Ala27Val), Ensembl rs2124888937, REVEL 0.22, CADD 21.20
- A28P (p.Ala28Pro), ExAC rs777142535, gnomAD rs777142535, REVEL 0.32, CADD 23.30
- A28V (p.Ala28Val), TOPMed rs996366201, gnomAD rs996366201, REVEL 0.25, CADD 23.20
- R29S (p.Arg29Ser), gnomAD rs1251620547, REVEL 0.28, CADD 23.00
- P30S (p.Pro30Ser), 1000Genomes rs558319702, ExAC rs558319702, TOPMed rs558319702, gnomAD rs558319702, REVEL 0.13, CADD 22.50, Uncertain significance, not specified
- S31P (p.Ser31Pro), Ensembl rs2124888876, REVEL 0.31, CADD 24.10
- G32A (p.Gly32Ala), Ensembl rs2124888856
- G32S (p.Gly32Ser), Ensembl rs61821692, REVEL 0.07, CADD 15.90
- R33G (p.Arg33Gly), ExAC rs747516775, TOPMed rs747516775, gnomAD rs747516775, REVEL 0.44, CADD 23.10
- R33H (p.Arg33His), Ensembl rs2124888825, REVEL 0.29, CADD 23.90
- R33P (p.Arg33Pro), Ensembl rs2124888825
- R33S (p.Arg33Ser), ExAC rs747516775, TOPMed rs747516775, gnomAD rs747516775, REVEL 0.42, CADD 22.90
- R34G (p.Arg34Gly), gnomAD rs1282734179, REVEL 0.19, CADD 22.80
- R34M (p.Arg34Met), NCI-TCGA TCGA novel, REVEL 0.30, CADD 23.40, Variant assessed as somatic; moderate impact.
- R34W (p.Arg34Trp), cosmic curated COSV99056, gnomAD rs1282734179, REVEL 0.30, CADD 24.40
- R35Q (p.Arg35Gln), Ensembl rs2124888800, REVEL 0.17, CADD 22.80
- R35W (p.Arg35Trp), Ensembl rs2124888805, REVEL 0.37, CADD 25.90
- D36A (p.Asp36Ala), Ensembl rs2124888787
- D36N (p.Asp36Asn), Ensembl rs2124888796, REVEL 0.07, CADD 21.30
- P37A (p.Pro37Ala), TOPMed rs1235370247, gnomAD rs1235370247, REVEL 0.10, CADD 19.90
- P37L (p.Pro37Leu), TOPMed rs1333357319, REVEL 0.17, CADD 21.40
- P37R (p.Pro37Arg), TOPMed rs1333357319, REVEL 0.12, CADD 22.90
- P37S (p.Pro37Ser), TOPMed rs1235370247, gnomAD rs1235370247, REVEL 0.10, CADD 22.10
- A38S (p.Ala38Ser), ExAC rs778308312, TOPMed rs778308312, gnomAD rs778308312, REVEL 0.12, CADD 18.20, Uncertain significance, not specified
- A38V (p.Ala38Val), gnomAD rs1393597219, REVEL 0.14, CADD 22.30
- G39R (p.Gly39Arg), ExAC rs772415670, TOPMed rs772415670, gnomAD rs772415670, REVEL 0.30, CADD 22.70
- G39W (p.Gly39Trp), cosmic curated COSV10085, ExAC rs772415670, TOPMed rs772415670, gnomAD rs772415670, REVEL 0.41, CADD 27.30, Uncertain significance, not specified
- R40C (p.Arg40Cys), TOPMed rs1344414390, REVEL 0.35, CADD 23.90
- R40G (p.Arg40Gly), TOPMed rs1344414390
- R40H (p.Arg40His), ExAC rs748250030, TOPMed rs748250030, gnomAD rs748250030, REVEL 0.25, CADD 23.80
- R40L (p.Arg40Leu), ExAC rs748250030, TOPMed rs748250030, gnomAD rs748250030, REVEL 0.30, CADD 23.70, Uncertain significance, not specified
- R40S (p.Arg40Ser), TOPMed rs1344414390, REVEL 0.30, CADD 22.90
- T41A (p.Thr41Ala), TOPMed rs1292951930, gnomAD rs1292951930, REVEL 0.15, CADD 12.50
- T42I (p.Thr42Ile), TOPMed rs1434957069, gnomAD rs1434957069, REVEL 0.16, CADD 19.30
- E43D (p.Glu43Asp), TOPMed rs868544684, REVEL 0.21, CADD 17.50
- G45A (p.Gly45Ala), TOPMed rs1050321732, gnomAD rs1050321732, REVEL 0.35, CADD 22.50
- G45R (p.Gly45Arg), ExAC rs754053173, TOPMed rs754053173, gnomAD rs754053173, REVEL 0.49, CADD 24.00
- G45S (p.Gly45Ser), ExAC rs754053173, TOPMed rs754053173, gnomAD rs754053173, REVEL 0.31, CADD 23.70
- F46L (p.Phe46Leu), Ensembl rs2124888629, REVEL 0.20, CADD 20.20
- F46S (p.Phe46Ser), Ensembl rs2124888636, REVEL 0.32, CADD 23.40
- N47D (p.Asn47Asp), ExAC rs779772886, gnomAD rs779772886, REVEL 0.23, CADD 24.30
- N47S (p.Asn47Ser), rs544043509, 1000Genomes rs544043509, ExAC rs544043509, TOPMed rs544043509, REVEL 0.20, CADD 23.60, Variant assessed as somatic; moderate impact.
- I48M (p.Ile48Met), TOPMed rs923070533, gnomAD rs923070533, REVEL 0.31, CADD 23.40
- I48V (p.Ile48Val), gnomAD rs1396896893, REVEL 0.17, CADD 17.20
- F49C (p.Phe49Cys), Ensembl rs1663409786, REVEL 0.51, CADD 24.90
- H52Q (p.His52Gln), gnomAD rs1259370913, REVEL 0.18, CADD 22.00
- H52R (p.His52Arg), Ensembl rs1663409450, REVEL 0.37, CADD 23.90
- D53H (p.Asp53His), gnomAD rs1211783768, REVEL 0.21, CADD 26.10
- H54Y (p.His54Tyr), TOPMed rs1656529052, gnomAD rs1656529052, REVEL 0.19, CADD 23.40
- F55C (p.Phe55Cys), Ensembl rs2102673376, REVEL 0.34, CADD 25.70
- V59L (p.Val59Leu), Ensembl rs962629923
- E60A (p.Glu60Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E60D (p.Glu60Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E60G (p.Glu60Gly), ExAC rs763588356, REVEL 0.30, CADD 32.00
- D61Y (p.Asp61Tyr), ExAC rs753133401, gnomAD rs753133401, REVEL 0.35, CADD 25.30
- F63C (p.Phe63Cys), ExAC rs765410093, TOPMed rs765410093, gnomAD rs765410093, REVEL 0.29, CADD 22.70
- E64K (p.Glu64Lys), ExAC rs759563551, gnomAD rs759563551, REVEL 0.27, CADD 23.70
- G65R (p.Gly65Arg), cosmic curated COSV10743, TOPMed rs1470099594, gnomAD rs1470099594, REVEL 0.32, CADD 24.90
- G65V (p.Gly65Val), Ensembl rs1656526343
- K67N (p.Lys67Asn), ExAC rs776800830, gnomAD rs776800830, REVEL 0.17, CADD 23.50
- G69E (p.Gly69Glu), TOPMed rs1656525141
- G69R (p.Gly69Arg), ExAC rs771287245, gnomAD rs771287245, REVEL 0.33, CADD 22.90
- G70S (p.Gly70Ser), ESP rs140292380, ExAC rs140292380, TOPMed rs140292380, gnomAD rs140292380, REVEL 0.18, CADD 19.80
- S71G (p.Ser71Gly), ExAC rs773207546, TOPMed rs773207546, gnomAD rs773207546, REVEL 0.09, CADD 16.90
- S71N (p.Ser71Asn), TOPMed rs1656524124
- S71T (p.Ser71Thr), TOPMed rs1656524124
- P73A (p.Pro73Ala), TOPMed rs1368682019, gnomAD rs1368682019, REVEL 0.21, CADD 19.20
- P73T (p.Pro73Thr), TOPMed rs1368682019, gnomAD rs1368682019
- E74Q (p.Glu74Gln), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10077, Variant assessed as somatic; moderate impact.
- H77Q (p.His77Gln), ExAC rs767384933, gnomAD rs767384933, REVEL 0.05, CADD 15.70
- H77R (p.His77Arg), ExAC rs773544977, TOPMed rs773544977, gnomAD rs773544977, REVEL 0.10, CADD 22.80
- R78C (p.Arg78Cys), rs371509729, ClinGen CA1265187, cosmic curated COSV61010, ClinVar RCV004200945, REVEL 0.26, CADD 30.00, Uncertain significance, not specified
- R78H (p.Arg78His), rs55655202, UniProt VAR 055411, 1000Genomes rs55655202, ExAC rs55655202, REVEL 0.11, CADD 24.00
- Y80C (p.Tyr80Cys), ESP rs140935116, ExAC rs140935116, TOPMed rs140935116, gnomAD rs140935116, REVEL 0.09, CADD 22.80, Uncertain significance, not specified
- C82F (p.Cys82Phe), 1000Genomes rs528004734, ExAC rs528004734, TOPMed rs528004734, gnomAD rs528004734, REVEL 0.16, CADD 22.10, Uncertain significance, not specified
- C82R (p.Cys82Arg), TOPMed rs1656320469
- D83G (p.Asp83Gly), ExAC rs745571219, TOPMed rs745571219, gnomAD rs745571219, REVEL 0.17, CADD 24.10
- D83H (p.Asp83His), TOPMed rs535204533, gnomAD rs535204533, REVEL 0.20, CADD 25.50
- V84I (p.Val84Ile), ExAC rs780680423
- E85D (p.Glu85Asp), ExAC rs756881677, TOPMed rs756881677, gnomAD rs756881677
- P86R (p.Pro86Arg), Ensembl rs2102665387
- P86S (p.Pro86Ser), gnomAD rs1421166797, REVEL 0.04, CADD 14.90
- Q87* (p.Gln87Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- Q87H (p.Gln87His), ExAC rs748473268, TOPMed rs748473268, gnomAD rs748473268
- Q87K (p.Gln87Lys), gnomAD rs1308100649, REVEL 0.09, CADD 23.10, Uncertain significance, not specified
- Q87R (p.Gln87Arg), TOPMed rs1229741523, gnomAD rs1229741523, REVEL 0.10, CADD 23.30
- A88S (p.Ala88Ser), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10077, NCI-TCGA Cosmic COSV6101, Ensembl rs1656314171, Uncertain significance
- A88T (p.Ala88Thr), NCI-TCGA Cosmic COSV1007, NCI-TCGA Cosmic COSV6101, cosmic curated COSV61012, Ensembl rs1656314171, REVEL 0.10, CADD 23.40, Uncertain significance, not specified
- N90H (p.Asn90His), ExAC rs755606411, TOPMed rs755606411, gnomAD rs755606411, REVEL 0.09, CADD 17.60
- E91* (p.Glu91Ter), NCI-TCGA Cosmic COSV6101, cosmic curated COSV61017, Variant assessed as somatic; high impact.
- E91Q (p.Glu91Gln), Ensembl rs2102665264
- A92T (p.Ala92Thr), TOPMed rs1201299762, gnomAD rs1201299762, REVEL 0.17, CADD 25.40
- I93L (p.Ile93Leu), ExAC rs753558280
- I93V (p.Ile93Val), ExAC rs753558280, REVEL 0.06, CADD 15.10
- R94M (p.Arg94Met), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10077, Variant assessed as somatic; moderate impact.
- R94W (p.Arg94Trp), ExAC rs766612998, gnomAD rs766612998, REVEL 0.54, CADD 26.40
- S96I (p.Ser96Ile), TOPMed rs1656311917, REVEL 0.24, CADD 24.80
- S97A (p.Ser97Ala), ExAC rs756229936, gnomAD rs756229936, REVEL 0.24, CADD 26.30
- K98E (p.Lys98Glu), ESP rs201376490, ExAC rs201376490, TOPMed rs201376490, gnomAD rs201376490, REVEL 0.36, CADD 27.50
- K98M (p.Lys98Met), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10077, Variant assessed as somatic; moderate impact.
- E99Q (p.Glu99Gln), UniProt VAR 055412, Uncertain significance
- L102F (p.Leu102Phe), gnomAD rs1204580093, REVEL 0.14, CADD 25.50
- G103R (p.Gly103Arg), rs187540054, ClinGen CA1265170, ClinVar RCV004354640, 1000Genomes rs187540054, REVEL 0.33, CADD 26.10, Uncertain significance, not specified
- A104T (p.Ala104Thr), cosmic curated COSV61021, Ensembl rs1656310240, REVEL 0.13, CADD 21.80
- E106D (p.Glu106Asp), ExAC rs763949080, gnomAD rs763949080, REVEL 0.13, CADD 22.70
- E106K (p.Glu106Lys), NCI-TCGA Cosmic COSV1007, cosmic curated COSV10077, Variant assessed as somatic; moderate impact.
- S107N (p.Ser107Asn), ESP rs370197732, ExAC rs370197732, TOPMed rs370197732, gnomAD rs370197732, REVEL 0.04, CADD 16.60
- N110D (p.Asn110Asp), gnomAD rs1340062027, REVEL 0.09, CADD 22.80
- F112L (p.Phe112Leu), ExAC rs200298102, TOPMed rs200298102, gnomAD rs200298102, REVEL 0.37, CADD 21.30
- V113I (p.Val113Ile), rs201168871, NCI-TCGA Cosmic COSV1007, cosmic curated COSV10077, NCI-TCGA Cosmic COSV6101, REVEL 0.11, CADD 23.00, Variant assessed as somatic; moderate impact.
- A114G (p.Ala114Gly), TOPMed rs1028542505, gnomAD rs1028542505, REVEL 0.77, CADD 26.30
- A114T (p.Ala114Thr), ExAC rs745401841, gnomAD rs745401841, REVEL 0.85, CADD 26.20
- Y116N (p.Tyr116Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- F118L (p.Phe118Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V119I (p.Val119Ile), ExAC rs746665603, gnomAD rs746665603, REVEL 0.16, CADD 23.40
- A120T (p.Ala120Thr), TOPMed rs1656306203, REVEL 0.42, CADD 26.10
- G122V (p.Gly122Val), TOPMed rs1408728156, gnomAD rs1408728156, REVEL 0.53, CADD 26.10
- T125K (p.Thr125Lys), ExAC rs749851427, gnomAD rs749851427, REVEL 0.45, CADD 26.90
- L126F (p.Leu126Phe), Ensembl rs2102664769
Public ABL2 analysis runs
- ABL2 analysis run — ABL2 (2,040 variants) — completed 2026-08-28